… To mitigate this concern and reduce the risk of bias, extensive peer review was completed
in addition to review and approval by the AHA’s Scientific Advisory Coordinating Committee …

Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or
statin therapy have demonstrated that baseline or treated low-density lipoprotein (LDL) …

Background Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. …

High-density lipoprotein (HDL) has been proposed to have several antiatherosclerotic
properties, including the ability to mediate macrophage cholesterol efflux, antioxidant capacity, …

Background Diabetic dyslipidemia is characterized by high triglyceride levels; low high-density
lipoprotein cholesterol levels; small, dense low-density lipoprotein particles; and high …

The burden of cardiovascular disease (CVD) among patients with diabetes is substantial.
Individuals with diabetes are at 2-to 4-fold increased risk of cardiovascular events compared …

Objectives : This study sought to evaluate the efficacy and safety of subcutaneous evolocumab
compared with oral ezetimibe in hypercholesterolemic patients who are unable to tolerate …

High-density lipoproteins (HDLs) protect against atherosclerosis by removing excess cholesterol
from macrophages through the ATP-binding cassette transporter A1 (ABCA1) and ATP-…

BACKGROUND A growing body of evidence from epidemiological data, animal studies, and
clinical trials supports HDL as the next target to reduce residual cardiovascular risk in statin-…

Importance Muscle-related statin intolerance is reported by 5% to 20% of patients. Objective
To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid…